arrow
J

Julie Rytlewski

Bristol Myers Squibb
H指数:19
被引数:4,548

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma

不同患者、肿瘤及嵌合抗原受体T细胞特征与伊decabtagene vicleucel在复发/难治性多发性骨髓瘤中启动与维持应答相关

2025-07-150
OA
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
2023-08-1745
OAAI
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence (vol 1, pg 197, 2020)

原发性黑色素瘤T细胞的分子分析确定有转移复发风险的患者 (第1卷,197页,2020)

2020-03-170
OAAI
Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence

原发性黑色素瘤T细胞的分子分析可确定有转移复发风险的患者

2020-01-2024
OAAI
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

新辅助anti-PD-1免疫疗法可通过肿瘤内和全身免疫反应促进复发性胶质母细胞瘤的生存益处

2019-02-11976
OAAI